Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Magrey

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Rheumatology (Oxford, England)|January 11, 2025
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
The Journal of Rheumatology|October 15, 2024
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE StudiesVictoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, et al.
Annals of the Rheumatic Diseases|October 4, 2023
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Advances in Rheumatology (London, England)|December 19, 2024
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitisAtul Deodhar, Servet Akar, Jeffrey R Curtis, et al.
Lancet (London, England)|July 3, 2018
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyRobert Landewé, Joachim Sieper, Philip Mease, et al.
Arthritis Care & Research|June 7, 2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisLenore Buckley, Gordon Guyatt, Howard A Fink, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 7, 2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisLenore Buckley, Gordon Guyatt, Howard A Fink, et al.
Annals of the Rheumatic Diseases|January 17, 2023
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trialsDésirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, et al.
RMD Open|January 19, 2021
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA studyClementina López-Medina, Anna Molto, Joachim Sieper, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Rheumatology (Oxford, England)|January 11, 2025
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
The Journal of Rheumatology|October 15, 2024
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE StudiesVictoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, et al.
Annals of the Rheumatic Diseases|October 4, 2023
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Advances in Rheumatology (London, England)|December 19, 2024
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitisAtul Deodhar, Servet Akar, Jeffrey R Curtis, et al.
Lancet (London, England)|July 3, 2018
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyRobert Landewé, Joachim Sieper, Philip Mease, et al.
Arthritis Care & Research|June 7, 2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisLenore Buckley, Gordon Guyatt, Howard A Fink, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 7, 2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisLenore Buckley, Gordon Guyatt, Howard A Fink, et al.
Annals of the Rheumatic Diseases|January 17, 2023
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trialsDésirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, et al.
RMD Open|January 19, 2021
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA studyClementina López-Medina, Anna Molto, Joachim Sieper, et al.
Pageof 7